Page 115 - ESHRE2019
P. 115
Differences in formation of epiblast/hypoblast
MAPK inhibition
100
75
25
100
75
50* 50
25
*
C PD
GATA6
C PD
NANOG
C PD03 C PD03
NANOG GATA6 Day 3‐6
Day 1‐8
Kuijk et al., 2012 Development 139, 871‐882
Pluripotent stem cells: the new patient?
Bellin et al., 2012 Nature Rev Mol Cell Biol, 13(11):713‐26
110
PRECONGRESS COURSE 13 I VIENNA, AUSTRIA – 23 JUNE 2019 113
Percentage
Percentage
